In Brief: Neozyme II/NABI HyperGAM+CF
Neozyme II/NABI HyperGAM+CF: Phase II trial for the treatment of severe Pseudomonas lung infections in cystic fibrosis patients discontinued after an interim analysis showed no reduction in acute pulmonary exacerbation. Neozyme owner Genzyme, which has marketing rights to NABI's HyperGAM+CF, said at the Alex. Brown analysts conference in May that the product had the potential to exceed the Ceredase/Cerezyme CF line in revenues. Genzyme and NABI had been in negotiations to modify the agreement so that Genzyme could terminate the deal upon receipt of the trial results ("The Pink Sheet" May 27, T&G-5)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth